Amgen's Repatha Gets Big Formulary Win With CVS Health
Evolocumab will be the only PCSK9 inhibitor on the PBM's commercial formulary, with Amgen agreeing to provide additional pricing discounts based on outcomes and utilization.
Evolocumab will be the only PCSK9 inhibitor on the PBM's commercial formulary, with Amgen agreeing to provide additional pricing discounts based on outcomes and utilization.